[HTML][HTML] Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18–45 years enrolled in a clinical trial
LH Wei, YY Su, YM Hu, RC Li, W Chen, QJ Pan… - Clinical Microbiology …, 2020 - Elsevier
Objectives Data from clinical trials of human papillomavirus (HPV) vaccines showed that
women naïve (negative for both type-specific antibodies and DNA) to vaccine types would …
women naïve (negative for both type-specific antibodies and DNA) to vaccine types would …
Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18–25 years enrolled in a clinical trial
FH Zhao, FC Zhu, W Chen, J Li, YM Hu… - … journal of cancer, 2014 - Wiley Online Library
Baseline human papillomavirus (HPV) prevalence and type distribution were evaluated in
young Chinese women enrolled in a clinical trial of an HPV vaccine (ClinicalTrials. gov …
young Chinese women enrolled in a clinical trial of an HPV vaccine (ClinicalTrials. gov …
[HTML][HTML] Human papillomavirus genotypic characteristics of 60,685 subjects under age-expansion vaccination of the nine-valent human papillomavirus vaccine: A …
Y Liu, Z Li, L Yuan, F Liu, K Wu, X Xiao… - Journal of Infection and …, 2023 - Elsevier
Background Human papillomavirus (HPV) vaccination is a key initiative to promote the WHO
global strategy to accelerate the elimination of cervical cancer, and this study aimed to …
global strategy to accelerate the elimination of cervical cancer, and this study aimed to …
Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9–45 years of age: A phase 3 open-label study
H Lv, S Wang, Z Liang, W Yu, C Yan, Y Chen, X Hu… - Vaccine, 2022 - Elsevier
Background The 9-valent human papillomavirus (9vHPV; HPV6/11/16/18/31/33/45/52/58)
vaccine was approved for use in Chinese women aged 16–26 years in 2018. This phase 3 …
vaccine was approved for use in Chinese women aged 16–26 years in 2018. This phase 3 …
Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 …
N Folschweiller, J Teixeira, S Joshi, LZ Goldani… - …, 2020 - thelancet.com
Background Women living with HIV (WLWH) are at higher risk of acquisition and
progression of human papillomavirus (HPV) infection. Evidence on effect of HPV vaccination …
progression of human papillomavirus (HPV) infection. Evidence on effect of HPV vaccination …
Why consider human papillomavirus vaccination in older women?
WA Poppe, PH Simon, MR De Ridder - Gynecologic and obstetric …, 2010 - karger.com
Preventive human papillomavirus (HPV) L1 vaccines are safe and efficient to prevent
infection and lesions of vaccine-specific HPV types in women from 15 to 26 years, but also in …
infection and lesions of vaccine-specific HPV types in women from 15 to 26 years, but also in …
Population‐based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese women
JS Smith, AK Lewkowitz, YL Qiao, J Ji… - … journal of cancer, 2012 - Wiley Online Library
To optimize HPV vaccination implementation at the population‐level in China, data are
needed on age‐specific HPV 16, 18, 6 and 11 prevalence. This cross‐sectional, population …
needed on age‐specific HPV 16, 18, 6 and 11 prevalence. This cross‐sectional, population …
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label …
EA Joura, A Ulied, C Vandermeulen, MR Figueroa… - Vaccine, 2021 - Elsevier
Background Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16–26 …
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16–26 …
Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women …
MH Einstein, P Takacs, A Chatterjee… - Human vaccines & …, 2014 - Taylor & Francis
The observer-blind, randomized, age-stratified, head-to-head study (NCT00423046)
comparing immunogenicity and safety of HPV-16/18 and HPV-6/11/16/18 vaccines in …
comparing immunogenicity and safety of HPV-16/18 and HPV-6/11/16/18 vaccines in …
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a Phase III …
MH Einstein, M Baron, MJ Levin, A Chatterjee… - Human …, 2011 - Taylor & Francis
In this observer-blind study (NCT00423046), women (N= 1,106), stratified by age (18–26, 27–
35, 36–45 years), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
35, 36–45 years), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …